BOOK
Clinical Psychiatry: Recent Advances and Future Directions, An Issue of Psychiatric Clinics of North America, E-Book
(2015)
Additional Information
Book Details
Abstract
Recent advances in clinical psychiatry are presented by David Baron and Lawrence Gross in this issue of Psychiatric Clinics. Psychiatrists will find here disorders they deal with daily in patients and topics include Advances in: Addictive disorders; Geriatric and healthy aging; Trauma and violence; PTSD; Schizophrenia; Intellectual disabilities; Neuropsychiatry, Psychopharmacology; Integrated care - psychiatry and primary care; Global and cultural psychiatry; Mood disorders. Also presented are the Future role of psychotherapy in psychiatry; Public mental health in the Affordable Care Act era; Genetics; and Diagnostic classification (DSM criteria) how they are transitioning in future - DSM V and beyond.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Clinical Psychiatry:Recent Advances andFuture Directions | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: Where Are We, and Where Are We Going? An Insider’s View…\r | vii | ||
| Schizophrenia Research: A Progress Report\r | vii | ||
| Development of New Psychopharmacological Agents for Depression and Anxiety\r | vii | ||
| Personalized Medicine and Mood Disorders\r | vii | ||
| Psychotherapy and Psychosocial Treatment: Recent Advances and Future Directions\r | viii | ||
| A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating ... | viii | ||
| Integrated Care at the Interface of Psychiatry and Primary Care: Prevention of Cardiovascular Disease\r | viii | ||
| The Next Big Thing in Child and Adolescent Psychiatry: Interventions to Prevent and Intervene Early in Psychiatric Illnesses\r | viii | ||
| Clinical Advances in Geriatric Psychiatry: A Focus on Prevention of Mood and Cognitive Disorders\r | ix | ||
| Complex Trauma in Adolescents and Adults: Effects and Treatment\r | ix | ||
| Facing Violence – A Global Challenge\r | ix | ||
| How Health Reform is Recasting Public Psychiatry\r | x | ||
| Telepsychiatry: Effective, Evidence-Based, and at a Tipping Point in Health Care Delivery?\r | x | ||
| PSYCHIATRIC CLINICS OF\rNORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| December 2015 | xi | ||
| March 2016 | xi | ||
| June 2016 | xi | ||
| RECENT ISSUES | xi | ||
| June 2015 | xi | ||
| March 2015 | xi | ||
| December 2014 | xi | ||
| Preface\r | xiii | ||
| Schizophrenia Research | 373 | ||
| Key points | 373 | ||
| CONCLUDING REMARKS | 375 | ||
| REFERENCES | 376 | ||
| Development of New Psychopharmacological Agents for Depression and Anxiety | 379 | ||
| Key points | 379 | ||
| KETAMINE AND GLUTAMATERGIC AGENTS | 381 | ||
| ALTERNATIVE GLUTAMATERGIC STRATEGIES | 383 | ||
| OBOTULINUM TOXIN | 384 | ||
| GLUCOCORTICOID ANTAGONISTS | 385 | ||
| OPIOIDS: MIXED AGONIST/ANTAGONISTS | 387 | ||
| FAILED STRATEGIES AND FAILED DEVELOPMENT EFFORTS | 387 | ||
| Corticotropin-Releasing Hormone Antagonists | 388 | ||
| AGOMELATINE | 388 | ||
| EDIVOXETINE AND LISDEXAMFETAMINE | 388 | ||
| REFERENCES | 390 | ||
| Personalized Medicine and Mood Disorders | 395 | ||
| Key points | 395 | ||
| INTRODUCTION | 395 | ||
| MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER | 397 | ||
| ALTERATIONS IN DRUG-METABOLIZING ENZYMES | 397 | ||
| CHANGES IN THE SEROTONERGIC SYSTEM | 397 | ||
| THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS | 398 | ||
| CIRCADIAN RHYTHM GENES ALTERATIONS | 399 | ||
| EPIGENETIC MODIFICATIONS | 399 | ||
| PREDICTORS OF TREATMENT RESPONSE | 400 | ||
| SUMMARY | 400 | ||
| FINANCIAL DISCLOSURES | 401 | ||
| REFERENCES | 401 | ||
| Psychotherapy and Psychosocial Treatment | 405 | ||
| Key points | 405 | ||
| POLICY AND LAW | 407 | ||
| PSYCHIATRY'S FALSE ASSUMPTIONS | 408 | ||
| False Assumption | 408 | ||
| False Assumption | 410 | ||
| False Assumption | 411 | ||
| HOW FALSE ASSUMPTIONS SHAPE THE FUTURE OF PSYCHOTHERAPY AND PSYCHOSOCIAL TREATMENT | 411 | ||
| EDUCATION AND THE FUTURE OF PSYCHOTHERAPY AND PSYCHOSOCIAL TREATMENT | 414 | ||
| SUMMARY | 415 | ||
| REFERENCES | 415 | ||
| A Shared Molecular and Genetic Basis for Food and Drug Addiction | 419 | ||
| Key points | 420 | ||
| INTRODUCTION | 420 | ||
| The Molecular Aspects of Dopamine in Reward Circuitry | 420 | ||
| Food Intake and Reward | 423 | ||
| Neurogenetics of Genes Relates to Eating Disorders | 424 | ||
| Dopamine D2 Receptor Gene | 438 | ||
| Other Dopamine Genes and Commonality | 440 | ||
| Can We Explain Relapse via Dopaminergic Genetics? | 440 | ||
| Dopaminergic Agonistic Therapy as a Common Treatment for Food and Drug Addiction | 441 | ||
| Pharmacologic Treatments | 443 | ||
| Nutrigenomic Treatments | 444 | ||
| Future Perspectives and Policy | 445 | ||
| SUMMARY | 447 | ||
| ACKNOWLEDGMENTS | 448 | ||
| REFERENCES | 448 | ||
| Integrated Care at the Interface of Psychiatry and Primary Care | 463 | ||
| Key points | 463 | ||
| MENTAL ILLNESS AND COMORBID GENERAL MEDICAL ILLNESS | 463 | ||
| PREVENTING MEDICAL ILLNESS IN THE PSYCHIATRIC SETTING | 464 | ||
| ASSESSING CARDIOVASCULAR RISK | 466 | ||
| HYPERTENSION | 467 | ||
| Diagnostic and Preventive Considerations | 467 | ||
| DIABETES | 468 | ||
| Diagnostic and Preventive Considerations | 468 | ||
| DYSLIPIDEMIA | 470 | ||
| Diagnostic and Preventive Considerations | 470 | ||
| PREVENTIVE GUIDELINES | 470 | ||
| FINAL THOUGHTS | 471 | ||
| REFERENCES | 472 | ||
| The Next Big Thing in Child and Adolescent Psychiatry | 475 | ||
| Key points | 475 | ||
| INTRODUCTION | 476 | ||
| Background | 477 | ||
| Treatment of Women with Depression During Pregnancy and Postpartum | 477 | ||
| Treatment of Mothers Who have Older Children | 478 | ||
| The Potential for Preventing Depression in Asymptomatic Youth Who have a Family History of Major Depression | 479 | ||
| Background | 480 | ||
| The PAX Good Behavior Game | 481 | ||
| Background | 483 | ||
| SPARX Video Game | 483 | ||
| Background | 486 | ||
| Description of Model Programs, Outcomes, and Treatment Elements | 487 | ||
| SUMMARY | 488 | ||
| REFERENCES | 489 | ||
| Clinical Advances in Geriatric Psychiatry | 495 | ||
| Key points | 495 | ||
| INTRODUCTION | 495 | ||
| CLINICAL ADVANCES IN GERIATRIC DEPRESSION | 496 | ||
| Preventive Interventions for Geriatric Depression | 496 | ||
| Resilience-Building Interventions | 498 | ||
| Complementary, Alternative, and Integrative Therapies for Geriatric Depression | 499 | ||
| Clinical importance | 500 | ||
| Conventional physical activity | 500 | ||
| Mind-body practices | 501 | ||
| Dietary interventions | 502 | ||
| CLINICAL ADVANCES IN COGNITIVE DECLINE AND DEMENTIA | 503 | ||
| Prevention of Cognitive Decline and Dementia | 503 | ||
| Complementary, Alternative, and Integrative Therapies for Cognitive Decline and Dementia | 504 | ||
| Conventional physical activity | 504 | ||
| Mindful exercise | 504 | ||
| Mind-body practices and stress-reduction techniques | 505 | ||
| Dietary interventions | 505 | ||
| Natural products | 506 | ||
| Ω3 polyunsaturated fatty acid supplements | 506 | ||
| Potential side effects and complementary, alternative, and integrative medicine-drug interactions | 507 | ||
| TELEPSYCHIATRY AND INTERNET-BASED APPROACHES FOR OLDER ADULTS | 507 | ||
| PROMISING RESEARCH AGENDAS | 509 | ||
| Geroscience | 509 | ||
| Health Neuroscience | 509 | ||
| Convergence Medicine | 510 | ||
| SUMMARY | 510 | ||
| REFERENCES | 510 | ||
| Complex Trauma in Adolescents and Adults | 515 | ||
| Key points | 515 | ||
| RISK OF POSTTRAUMATIC STRESS DISORDER | 516 | ||
| RISK OF COMPLEX OUTCOMES | 516 | ||
| TREATMENT OF COMPLEX TRAUMA-RELATED DISTURBANCE | 517 | ||
| Psychological Interventions | 518 | ||
| Cognitive-behavioral | 518 | ||
| Affect regulation training | 518 | ||
| Psychodynamic | 518 | ||
| Multi-target therapies | 518 | ||
| Pharmacotherapeutic Interventions | 519 | ||
| Pharmacotherapy of Posttraumatic Stress Disorder | 519 | ||
| Antidepressants | 519 | ||
| Benzodiazepines | 520 | ||
| Mood stabilizers | 520 | ||
| Adrenergic agents | 520 | ||
| Antipsychotics | 520 | ||
| Pharmacotherapy of Dissociation | 521 | ||
| Pharmacotherapy for Self-capacity Disturbance | 521 | ||
| SUMMARY | 521 | ||
| REFERENCES | 522 | ||
| Facing Violence – A Global Challenge | 529 | ||
| Key points | 529 | ||
| INTRODUCTION | 529 | ||
| VIOLENCE | 530 | ||
| Diagnostic Considerations | 530 | ||
| Interventions | 532 | ||
| Primary prevention | 532 | ||
| Secondary prevention | 533 | ||
| Treatment and tertiary prevention | 533 | ||
| DISPLACEMENT AS AN ADDITIONAL CHALLENGE | 535 | ||
| SUMMARY | 537 | ||
| REFERENCES | 537 | ||
| How Health Reform is Recasting Public Psychiatry | 543 | ||
| Key points | 543 | ||
| INTRODUCTION | 543 | ||
| A RECENT HISTORY OF PUBLIC PSYCHIATRY IN THE UNITED STATES | 544 | ||
| TOWARD A NEW PUBLIC PSYCHIATRY | 545 | ||
| Changes in Patient Population | 545 | ||
| New Community Mental Health Center Psychiatric Consultation and Collaboration | 546 | ||
| Worksite Transformation | 547 | ||
| New Forms of Care Management | 548 | ||
| SPECIAL ISSUES | 549 | ||
| The Impact of Funding Sources and Methodology in the Growth and Development of Community Psychiatry | 549 | ||
| The Recovery Movement in Integrated Health Care Settings | 550 | ||
| Health Reform and the Future of Involuntary Treatment | 551 | ||
| Academia and Public Psychiatry | 552 | ||
| An Agenda for Public Psychiatric Leadership in Health Care Reform | 553 | ||
| REFERENCES | 554 | ||
| Telepsychiatry | 559 | ||
| Key points | 559 | ||
| INTRODUCTION | 559 | ||
| HOW CAN THE EVIDENCE BASE FOR TELEPSYCHIATRY TO CLINICAL PRACTICE BE APPLIED? | 560 | ||
| Identification Info | 560 | ||
| History of Present Illness and Referral | 560 | ||
| TELEPSYCHIATRY IS EFFECTIVE | 561 | ||
| Clinical Outcome Evidence | 561 | ||
| Consultation and Technology | 561 | ||
| Evaluation | 561 | ||
| Application to the Clinical Vignette | 572 | ||
| Psychotherapy Evidence Base | 572 | ||
| HOW CAN CURRENT SYSTEMS OF CARE BE CHANGED AND TELEPSYCHIATRY (EG, USE TECHNOLOGY, GET PAID, AND ADHERE TO REGULATORY ISSUE ... | 575 | ||
| Overview | 575 | ||
| Organizational Leadership and Program Evaluation | 575 | ||
| Technology | 575 | ||
| Credentialing, Licensing, and Malpractice | 576 | ||
| Reimbursement | 576 | ||
| Application to the Clinical Vignette | 576 | ||
| MODELS OF CARE: THE E-CONTINUUM TOWARD INTEGRATED AND STEPPED CARE FOR DIFFERENT POPULATIONS, DISORDERS, AND TREATMENTS | 576 | ||
| Models of Care: How to Select Them and Impact on Evaluation | 576 | ||
| Low intensity | 576 | ||
| Moderate intensity | 577 | ||
| High intensity | 577 | ||
| Integrated Care | 577 | ||
| Patient-Centered Medical Home | 577 | ||
| Internet or Web-Based Care | 578 | ||
| WHAT CAN BE LEARNED AND WHAT MUST BE CONTENDED WITH, IN TERMS OF EMERGING MODELS OF E-CARE AND COMMUNICATION? | 578 | ||
| Digital Communication—e-Mail, Messaging Services, Web Sites, and Online Profiles | 579 | ||
| Social Media Communication | 579 | ||
| Advantages of social media | 579 | ||
| Cautions about, and guidelines for, social media use | 579 | ||
| The future virtual presence for doctors | 581 | ||
| Application to the Clinical Vignette | 581 | ||
| DISCUSSION, CLINICAL VIGNETTE PART II, AND SUMMARY | 581 | ||
| ACKNOWLEDGMENTS | 582 | ||
| REFERENCES | 582 | ||
| Index | 593 |